



2021 Virtual Congress – Scientific Program

All program timing in CEST

Pre-Congress, Thursday, May 6th	
13:30-15:00	Managing emerging toxicities with novel treatments in myeloma <i>Springer Healthcare IME Independent, CME Accredited Symposium</i>
Day 1, Friday, May 7th	
11:45-13:15	B-cell maturation antigen (BCMA)-targeted agents: Emerging clinical considerations for a new pillar of therapy for the treatment of relapsed/refractory multiple myeloma (RRMM) <i>Industry Symposium</i>
13:15-13:30	Welcome by Congress chairs
13:30-15:00	Session 1: High risk disease biology
13:30-13:45	Disease risk scoring Hervé Avet-Loiseau, France
13:45-14:00	Genomics of high-risk myeloma Nikhil Munshi, USA
14:00-14:15	Drug resistance in Myeloma Keith Stewart, Canada
14:15-15:00	Round table debate Moderators: Gordon Cook, UK and Keith Stewart, Canada <i>Speakers and, Gordon Cook, UK, Gareth Morgan, USA</i>
15:00-16:30	Session 2: Immune deregulation in myeloma
15:00-15:15	Role of the microenvironment Irene Ghobrial, USA
15:15-15:30	Mechanisms of resistance to immunotherapy Niels van de Donk, Netherlands
15:30-15:45	Strategies to reverse immune deregulation in myeloma Paola Neri, Canada
15:45-16:30	Round table debate Moderator: Michael O'Dwyer, Ireland <i>Speakers and, Michael O'Dwyer, Ireland, Bertrand Arnulf, France, Marc Raab, Germany</i>
16:30-18:00	Close combat: bringing the immune system in to defeat multiple myeloma <i>Industry Symposium</i>
18:00-19:15	Session 3: Plenary lectures
18:00-18:25	Therapy of AL amyloidosis: an update Giampaolo Merlini, Italy
18:25-18:50	Therapy of Waldenstrom macroglobulinemia Steve Treon, USA
18:50-19:15	Round table debate Moderators: Thierry Facon, France and Mohamad Mohty, France <i>Speakers and, Jorge Castillo, USA</i>
19:15-20:45	Should cure be the goal for multiple myeloma? <i>Non-profit Symposium</i>



Day 2, Saturday, May 8th	
10:00-11:00	Session 4: Snapshot talks (part 1) - Latest data
10:00-10:10	Latest data on HDAC inhibitors Enrique Ocio , Spain
10:10-10:20	Latest data on Targeting SLAMF7 Katia Weisel , Germany
10:20-10:30	Latest data on targeting Bcl2 inhibitors Cyrille Touzeau , France
10:30-10:45	Latest data on biphosphonates Evangelos Terpos , Greece
10:45-10:55	Latest data on antibody drug conjugates Suzanne Trudel , Canada
10:55-11:05	Latest data in extra-medullary disease Artur Jurczynszyn , Poland
11:05-12:20	Session 5: Snapshot talks (part 2) - Clinical trials updates
11:05-11:15	IFM 2009 Aurore Perrot , France
11:15-11:25	Carfilzomib, lenalidomide, and dexamethasone plus transplant Andrzej Jakubowiak , USA
11:25-11:35	GRIFFIN Jonathan Kaufman , USA
11:35-11:45	MASTER Luciano Costa , USA
11:45-11:55	IKEMA Tom Martin , USA
11:55-12:05	CANDOR Saad Usmani , USA
12:05-12:30	Q&A Moderators: Arnon Nagler and Evangelos Terpos , Greece
12:30-13:45	<i>Cellular therapies: perspectives for practice</i> <i>Industry Symposium</i>
13:45-15:00	Session 6: Therapy of young patients
13:45-14:00	The optimal induction regimen Philippe Moreau , France
14:00-14:15	Role of consolidation (including double auto-transplant) Michele Cavo , Italy
14:15-14:30	Maintenance approaches post-transplant Francesca Gay , Italy
14:30-15:00	Round table debate Moderators: Mohamad Mohty , France and Philippe Moreau , France <i>Speakers and</i> , Peter Sonneveld , Netherlands, Joan Blade , Spain, Muzaffar Qazilbash , USA



15:00-16:15	Session 7: Therapy of elderly patients Moderator: Meral Beksac , Turkey
15:00-15:15	IMiD-based approaches Thierry Facon , France
15:15-15:30	Management of elderly myeloma: PLS based approaches Marivi Mateos , Spain
15:30-15:45	Personalized treatment of the elderly Sonja Zweegman , Netherlands
15:45-16:15	Round table debate Moderators: Meral Beksac , Turkey and Mohamad Mohty , France <i>Speakers and</i> , Alessandra Larocca , Italy, Meral Beksac , Turkey
16:15-17:45	<i>Out of the Trial and into the Real World: Closing the Gap in RRMM Industry Symposium</i>
17:45-18:45	Session 8: Therapy of smoldering myeloma – a debate
17:45-18:00	Pro S. Vincent Rajkumar , USA
18:00-18:15	Con Xavier Leleu , France
18:15-18:45	Round table debate Moderator: Arnon Nagler , Israel <i>Speakers and</i> , Shaji Kumar , USA, Aurore Perrot , France, Rafat Abonour , USA
18:45-20:00	Session 9: Plenary lectures
18:45-19:10	MRD-based therapy: hope, hype, or reality? Jesus San Miguel , Spain
19:10-19:35	How to extend survival at relapse? Meletios Dimopoulos , Greece
19:35-20:00	Round table debate Moderator: Mohamad Mohty , France <i>Speakers and</i> , Jean-Luc Harousseau , France, Nizar Bahlis , Canada, Kwee Yong , UK, Saad Usmani , USA
20:00-21:00	<i>Measurable Residual Disease in Multiple Myeloma: A Real-World Experience Perspective Industry Symposium</i>



Day 3, Sunday, May 9th	
10:00-11:00	ORAL PRESENTATIONS
11:00-12:20	Session 10: Snapshot talks - Practical considerations
11:00-11:10	Practical considerations when using anti-CD38 antibodies Torben Plesner , Denmark
11:10-11:20	Management of cardiovascular adverse events Inger Nijhof , Netherlands
11:20-11:30	MRD monitoring: when, how and in which patient? Bruno Paiva , Spain
11:30-11:40	MGUS diagnosis: a step by step approach Graham Jackson , UK
11:40-11:50	Imaging: the essential work-up Elena Zamagni , Italy
11:50-12:00	COVID-19 vaccination in myeloma Heinz Ludwig , Austria
12:00-12:20	Q&A Moderators: Graham Jackson , UK and Heinz Ludwig , Austria
12:20-13:30	<i>Managing multiple myeloma at first relapse: Emerging treatment paradigms</i> <i>Industry symposium</i>
13:30-14:30	Session 11: Bispecific antibodies forum Moderator: Luciano Costa , USA
13:30-13:45	The case for BCMA as a target Alfred Garfall , USA
13:45-14:00	The case for non-BCMA targets Ajai Chari , USA
14:00-14:30	Round table debate Moderators: Luciano Costa , USA and Mohamad Mohty , France <i>Speakers and</i> , Adam Cohen , USA, Hermann Einsele , Germany, Luciano Costa , USA
14:30-15:30	Session 12: CAR-T cells forum
14:30-14:45	The case for Ide-Cel Noopur Raje , USA
14:45-15:00	The case for Cilta-Cel Deepu Madduri , USA
15:00-15:30	Round table debate Moderators: Arnon Nagler , Israel and Mohamad Mohty , France <i>Speakers and</i> , Nina Shah , USA, Arnon Nagler , Israel, Salomon Manier , France, Caitlin Costello , USA



15:30-16:30	Session 13: Novel drugs forum
15:30-15:40	Melflufen-based combinations Paul Richardson , USA
15:40-15:50	Iberdomide-based combinations Sagar Lonial , USA
15:50-16:00	XPO inhibitors Mohamad Mohty , France
16:00-16:10	Venetoclax: for which patients? Rafael Fonseca , USA
16:10-16:30	Round table debate Moderator: Rafael Fonseca , USA Speakers
16:30-17:30	<i>Uncharted territories: the expanding RRMM treatment landscape Industry Symposium</i>
17:30-18:00	Session 14: Plenary lecture
17:30-18:00	Multiple myeloma in 2025: the next steps? Kenneth Anderson , USA
18:00-18:30	Awards Ceremony